---
document_datetime: 2025-07-11 09:21:38
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/capecitabine-teva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: capecitabine-teva-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.3078814
conversion_datetime: 2025-12-30 00:15:58.997311
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Capecitabine Teva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0042              | A.7 - Administrative change - Deletion of manufacturing sites                                                                                         | 31/01/2024                          |                                             | Annex II and PL                  |           |
| IA/0041              | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate | 22/09/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                                             |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------|
| IA/0040/G | for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer A.7 - Administrative change - Deletion of                                       | 27/02/2023 | n/a | This was an application manufacturing sites |
| IA/0039/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 31/08/2021 | n/a |                                             |
| IB/0038/G | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.3.z - Change in the manufacturing process of                                                                                                                                                                                                          | 19/08/2021 | n/a |                                             |

<div style=\"page-break-after: always\"></div>

|           | the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                                  |                                                                                         |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------|
| N/0037    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 23/07/2021 | 22/03/2022 | PL                               |                                                                                         |
| IAIN/0036 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 24/02/2021 | 22/03/2022 | SmPC and PL                      |                                                                                         |
| A31/0031  | Pursuant to Article 31 of Directive 2001/83/EC, France requested on 13 March 2019 the opinion of the European Medicines Agency to assess the need to take action at EU level regarding the detection of DPD deficient patients (especially through genotyping and/or phenotyping) in patients treated with fluorouracil and related substances (capecitabine, tegafur and flucytosine). The Agency was requested to assess the impact thereof on the benefit-risk balance of fluorouracil and related substances containing products and to give its opinion on whether the marketing authorisation of these products should be maintained, varied, suspended or revoked. | 30/04/2020 | 03/07/2020 | SmPC and PL                      | Please refer to the assessment report: Capecitabine Teva EMEA/H/A-31/1481/C/002362/0031 |
| IB/0034   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                              | 05/06/2020 | 17/07/2020 | SmPC, Annex II, Labelling and PL |                                                                                         |

<div style=\"page-break-after: always\"></div>

| IAIN/0035   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                  | 02/06/2020   | n/a        |             |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|
| IB/0033     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                        | 25/09/2019   | 17/10/2019 | SmPC and PL |
| IB/0032     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                        | 06/06/2019   | 17/10/2019 | SmPC and PL |
| IB/0029/G   | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 06/11/2018   | n/a        |             |
| IB/0030     | C.I.2.a - Change in the SPC, Labelling or PL of a                                                                                                                                                                                                                                                                                                                                                   | 18/10/2018   | 17/10/2019 | SmPC,       |

<div style=\"page-break-after: always\"></div>

|             | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                             |            |            | Labelling and PL                 |                                                                                                                                                                                                                                                                                 |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0028/G | This was an application for a group of variations. B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 02/10/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                                 |
| N/0027      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                       | 01/02/2018 | 17/10/2019 | PL                               |                                                                                                                                                                                                                                                                                 |
| R/0025      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                | 10/11/2016 | 09/01/2017 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Capecitabine Teva in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0026     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                           | 16/09/2016 | 09/01/2017 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| IB/0023   | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 11/08/2016   | n/a   |                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------------|
| IA/0024/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                         | 01/08/2016   | n/a   |                     |
| IB/0022/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of | 20/04/2016   | n/a   | a Member State - AS |

<div style=\"page-break-after: always\"></div>

|             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                        | 26/02/2016   | 31/03/2016   | SmPC and PL         | IB/0021   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------------|-----------|
| IA/0020/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 05/08/2015   | n/a          |                     |           |
| IAIN/0019/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS                                               | 24/06/2015   | n/a          |                     |           |
| IB/0018     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following                                                                                                                                                                                                                                                                                                                      | 19/05/2015   | 31/03/2016   | SmPC, Labelling and |           |

<div style=\"page-break-after: always\"></div>

|             | of the same change for the reference - Implementation of change(s) for which NO additional data is required to be submitted by MAH                                                                                                                                                                                                                                                                                                                                                                                                |            |            | PL                     | assessment product new the   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------|
| T/0017      | Transfer of Marketing Authorisation from Teva Pharma B.V. (Utrecht) to Teva B.V. (Haarlem). Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                   | 04/11/2014 | 21/11/2014 | SmPC, Labelling and PL |                              |
| IAIN/0016/G | This was an application for a group of variations. B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished | 01/08/2014 | n/a        |                        | product                      |
| IA/0015/G   | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.b - Change in the specification parameters an AS, starting                                                                                                                                                                                                                                                | 17/06/2014 | n/a        |                        | and/or limits of             |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate/reagent - Tightening of limits - Change in the specification parameters limits of an AS, starting material/intermediate/reagent - Tightening of limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |             | specification B.I.b.1.b and/or specification   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------|
| IB/0014/G | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished Deletion of a non-significant in-process test                                                                                                                                                                                                                                                                                                                                                                | 15/04/2014 | n/a        |             | product -                                      |
| IB/0013/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following | 03/04/2014 | 21/11/2014 | SmPC and PL |                                                |

<div style=\"page-break-after: always\"></div>

|           | same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                        |            |            |                 | assessment of the   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------------------|
| IA/0012/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of | 28/11/2013 | n/a        |                 | specification       |
| IAIN/0011 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                          | 14/10/2013 | 20/02/2014 | Annex II and PL |                     |

<div style=\"page-break-after: always\"></div>

| II/0002/G   | This was an application for a group of variations.                                                                                                                                                                                                                                           | 19/09/2013   | n/a        |                                  |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|
| IB/0010     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                               | 11/09/2013   | 20/02/2014 | SmPC, Annex II, Labelling and PL |
| IB/0006/G   | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products | 05/08/2013   | 20/02/2014 | Annex II and PL                  |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0008/G | This was an application for a group of variations. B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                        | 29/07/2013 | n/a |
| IB/0007/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                                                                                                                                                                                                                            | 21/06/2013 | n/a |

<div style=\"page-break-after: always\"></div>

|           | to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure   |            |     | changes   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IA/0009/G | This was an application for a group of variations. B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                               | 03/06/2013 | n/a |           |
| IAIN/0005 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 28/05/2013 | n/a |           |

<div style=\"page-break-after: always\"></div>

| IAIN/0004   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                             | 11/04/2013   | n/a        |             |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|
| IAIN/0003   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                             | 11/04/2013   | n/a        |             |
| IB/0001     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 06/03/2013   | 20/02/2014 | SmPC and PL |